Cigna Investments Inc. New lowered its stake in Humana Inc. (NYSE:HUM) by 7.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,771 shares of the insurance provider’s stock after selling 451 shares during the period. Cigna Investments Inc. New’s holdings in Humana were worth $1,391,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Candriam Luxembourg S.C.A. increased its position in shares of Humana by 831.9% in the first quarter. Candriam Luxembourg S.C.A. now owns 70,001 shares of the insurance provider’s stock worth $14,431,000 after buying an additional 62,489 shares during the period. Hermes Investment Management Ltd. increased its position in shares of Humana by 0.9% in the first quarter. Hermes Investment Management Ltd. now owns 78,911 shares of the insurance provider’s stock worth $16,267,000 after buying an additional 700 shares during the period. State of Alaska Department of Revenue acquired a new position in shares of Humana during the first quarter worth about $342,000. Columbus Circle Investors increased its position in shares of Humana by 97.4% in the first quarter. Columbus Circle Investors now owns 13,623 shares of the insurance provider’s stock worth $2,808,000 after buying an additional 6,722 shares during the period. Finally, Granite Investment Advisors LLC increased its position in shares of Humana by 12.1% in the first quarter. Granite Investment Advisors LLC now owns 2,410 shares of the insurance provider’s stock worth $497,000 after buying an additional 260 shares during the period. Institutional investors and hedge funds own 99.66% of the company’s stock.

Shares of Humana Inc. (NYSE HUM) opened at 254.96 on Thursday. The firm’s 50-day moving average price is $238.81 and its 200-day moving average price is $222.35. The stock has a market capitalization of $36.85 billion, a P/E ratio of 20.97 and a beta of 0.91. Humana Inc. has a 12 month low of $163.50 and a 12 month high of $255.10.

Humana (NYSE:HUM) last released its earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.08 by $0.41. The business had revenue of $13.53 billion for the quarter, compared to analyst estimates of $13.61 billion. Humana had a net margin of 3.37% and a return on equity of 15.85%. During the same period last year, the company posted $2.30 EPS. On average, equities research analysts forecast that Humana Inc. will post $11.55 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Cigna Investments Inc. New Sells 451 Shares of Humana Inc. (NYSE:HUM)” was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/08/10/cigna-investments-inc-new-sells-451-shares-of-humana-inc-nysehum.html.

A number of research analysts have issued reports on HUM shares. Zacks Investment Research upgraded Humana from a “hold” rating to a “buy” rating and set a $237.00 price objective for the company in a research note on Tuesday, April 18th. Jefferies Group LLC cut Humana from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $237.00 to $221.00 in a report on Friday, April 21st. Cowen and Company reaffirmed an “outperform” rating and issued a $230.00 price target on shares of Humana in a report on Tuesday, April 25th. Evercore ISI reaffirmed an “outperform” rating and issued a $240.00 price target on shares of Humana in a report on Tuesday, April 25th. Finally, Cantor Fitzgerald raised their price target on Humana from $190.00 to $200.00 and gave the company a “neutral” rating in a report on Wednesday, April 26th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the company. Humana presently has a consensus rating of “Hold” and an average price target of $243.65.

In other news, VP Heidi S. Margulis sold 1,500 shares of Humana stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $231.96, for a total transaction of $347,940.00. Following the sale, the vice president now owns 8,150 shares of the company’s stock, valued at approximately $1,890,474. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Brian P. Leclaire sold 4,971 shares of Humana stock in a transaction that occurred on Wednesday, June 28th. The shares were sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the sale, the senior vice president now directly owns 14,258 shares in the company, valued at approximately $3,421,920. The disclosure for this sale can be found here. 0.80% of the stock is currently owned by insiders.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.